HHS oversight could force tighter limits on premiums
The Patient Protection and Affordable Care Act provides inroads for federal oversight of "unreasonable" increases in premiums in Section 2794.
FEDERAL FINANCIAL BACKING
It also is too early to tell how, if at all, Section 2794 will impact the end game for increases in premiums. Whether public disclosure on the Internet will result in muted increases is an open question.
More likely is that any real constraint on increases will come through the states, including changes to state laws that may provide more strict limits on increases. Insurers should stay attuned to governmental activities at the state level in order to ensure an appropriate review process, and stay tuned for further trends as Section 2794 plays out.
Christopher Williams is a partner with Calfee, Halter & Griswold LLP.
Laura McBride is an associate with Calfee, Halter & Griswold LLP.
Conversations With Perry and Friends
April 14th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. His guest this episode is John Baackes, the former CEO of L.A. Care Health Plan.
Listen
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Phase 3 Trial of Vertex’s Islet Cell Therapy for Type 1 Diabetes Under Way
April 23rd 2025Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes.
Read More
